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Abstract
In sequential experiments, subjects become available for the study over a period of time, and covariates
are often measured at the time of arrival. We consider the setting where the sample size is fixed but
covariate values are unknown until subjects enrol. Given a model for the outcome, a sequential optimal
design approach can be used to allocate treatments to minimize the variance of the treatment effect.
We extend existing optimal design methodology so it can be used within a nonmyopic framework,
where treatment allocation for the current subject depends not only on the treatments and covariates
of the subjects already enrolled in the study, but also the impact of possible future treatment assign-
ments. The nonmyopic approach is computationally expensive as it requires recursive formulae. We
propose a pseudo-nonmyopic approach which has a similar aim to the nonmyopic approach, but does
not involve recursion and instead relies on simulations of future possible decisions. Our simulation
studies show that the myopic approach is the most efficient for the logistic model case with a single
binary covariate and binary treatment.
Keywords: design of experiments, optimal design, dynamic programming, sequential design, coordi-
nate exchange
1 Introduction
How treatments should be allocated in sequential experiments in the presence of covariates is a highly
debated topic, particularly within the clinical trials community (Senn, 2013; Rosenberger and Sverdlov,
2008). We consider experiments where subjects become available sequentially, covariates are measured
at the time of arrival, and treatment is assigned soon after. We assume that a response is measured
before the next subject arrives, and we assume a fixed sample size. At any point in the experiment,
the covariate values for the subjects yet to enrol in the experiment are unknown. Such a set-up is
often characteristic of large Phase III trials, but is also common in experiments in the social sciences,
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such as political psychology lab experiments (Moore and Moore, 2013). Covariates should be included
in the analysis; omitting them results in bias (Senn, 2013), and further, from an optimal design point
of view, the allocation of treatment should be done in a way that maintains as equal replication as
possible of treatment within covariate groups, which improves precision of the parameter estimates
(Atkinson, 1982).
Minimization is an approach aimed to keep the numbers of treatments approximately equal for each
group of subjects who have the same combination of covariate values and is now used extensively in
clinical trials (Pocock and Simon, 1975; Taves, 1974). It has received some criticism for being based
on measures of imbalance of covariates which are not theoretically grounded (Senn et al., 2010) and
methods based on minimizing the variance of the parameter estimators in statistical models have
been suggested instead, originally by Atkinson (1982). Atkinson’s optimal design approach aims to
minimize the variance of the estimator of the treatment effect for a linear model which describes the
relationship between the treatments, covariates and response. The DA-optimal objective function
is used to make decisions for treatment allocation. We generalize Atkinson’s approach for the logis-
tic model case, which can be applied to any information matrix-based optimality criterion in Section 2.
The sequential optimal design approach is myopic in the sense that decisions are made using informa-
tion about the past subjects’ covariates, treatments and response and the current subject’s covariates.
The decision about the current subject is made assuming that the experiment will terminate after its
response is recorded, ignoring the fact that there are further subjects which will enter the trial, and the
estimates of interest are based on data from the entire experiment. Nonmyopic approaches are able
to consider the potential impact of the current treatment decision on future possible decisions (Huan
and Marzouk, 2016) in terms of efficiency of the estimators. In this paper, we assess whether there is
a benefit, in terms of efficiency of the estimators, in taking into account the impact of future possible
decisions. This relies on the method of dynamic programming to compute the expected value of the
objective function, where the expectation is taken over unknown quantities of future subjects (Bradley
et al., 1977, p. 323). Most applications of nonmyopic approaches in clinical trials aim to maximize
some measure of benefit of the treatment to the subject. The Gittens index is an example of such a
nonmyopic approach (Gittins and Jones, 1979; Smith and Villar, 2018; Williamson et al., 2017; Villar
and Rosenberger, 2018). Nonmyopic approaches for a clinical trials based problem involving covariates
where the objective is related to the estimation of parameters have not been explored explicitly in
the literature. We address this in Section 3 and compare the myopic and nonmyopic approaches in a
simulation study.
The nonmyopic approach is computationally expensive which limits its use in practical settings. We
propose the pseudo-nonmyopic approach in Section 4, which has a similar aim to the nonmyopic
approach but does not require recursive formulae. We compare how it fares against the myopic
approach in a simulation. We discuss our findings and potential extensions of our work in Section 5.
2
2 Myopic Sequential Design
2.1 Optimal Design
Suppose there are n subjects in total in an experiment, which is fixed from the start. For i ∈ {1, ..., n},
we observe the values of the s covariates associated with unit i
zi =
(
zi,1, ..., zi,s
)T
, (1)
and we select a treatment ti from a set of possible treatments T . We observe the response yi, which
we assume is binary and zero is the desirable response. We define the following:
Zi =

zT1
zT2
...
zTi
 ,
ti =
(
t1, t2, ..., ti
)T
,
yi =
(
y1, y2, ..., yi
)T
,
to be the i× s matrix of covariate values, the i-vector of treatments and i-vector of responses, respec-
tively, for subjects 1 up to i.
Given that yi has distribution
yi ∼ Bernoulli(pii), (2)
we assume a logistic regression for the response, where the probability pii = P (yi = 1) is given by
pii =
exp ηi
1 + exp ηi
, (3)
where ηi is the linear predictor. We assume ηi is a linear combination of the intercept, main effects
for the covariates and treatment, and potentially interaction terms. We denote the number of terms
in the linear predictor by q and assume it takes the following form:
ηj = xjβ, (4)
where xj is the jth row of the i × q design matrix Xi , for j ∈ {1, ..., i}, and we denote by β the
associated q-vector of parameter values. We can write the information matrix as I = XTi WiXi, where
Wi is a diagonal matrix with (j, j)th entry given by pˆij(1 − pˆij). There is a close link between the
information matrix and the variance of the parameter values; the maximum likelihood estimator of β
has asymptotic variance-covariance matrix given by the inverse of the information matrix:
Var(β) =
(
X>i WiXi
)−1
.
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In optimal design theory, decisions about treatments are made to minimize some function of
(
X>i WiXi
)−1
.
A D-optimal design minimizes the determinant of the inverse of the information matrix, or equiva-
lently, it minimizes the volume of the confidence ellipsoid of β (Atkinson et al., 2007, p. 53). The
D-optimal objective function, assessing the choice of treatments of the subjects enrolled in the study
t1, ..., ti, is given by:
ΨD(Xi,β) =
∣∣∣(XTi WiXi)−1∣∣∣ , (5)
where |·| denotes the determinant. One may have interest only in a subset of the parameters, or in
some linear combination of them. Supposing that interest lies in m linear combinations of β, the
quantity of interest can be expressed as ATβ, where A is a q×m matrix with m < q (Atkinson et al.,
2007, p.137). The asymptotic variance-covariance matrix for ATβ is given by:
Var
(
ATβ
)
= AT
(
XTi WiXi
)−1
A. (6)
In this case, the DA-optimality criterion is more appropriate:
ΨDA(Xi,β) =
∣∣∣AT (XTi WiXi)−1A∣∣∣ . (7)
In our case, we are interested in estimating the treatment effect as precisely as possible, A is a q-vector
with entry one corresponding to the treatment effect and zeros otherwise. If we wish to evaluate the
decision for the ith treatment given the covariates of subjects 1 up to i, Zi, the treatments of the
previous subjects, ti−1, and the responses of previous subjects, yi−1, we can denote the value of a
generic objective function evaluated when treatment ti is assigned to subject i as
Ψ(ti | Zi, ti−1,yi−1), (8)
where Ψ could be the D- or DA-, or some other information matrix based objective function. In a
non-sequential setting, an optimal allocation of treatments ti for a design with i subjects Xi can be
constructed using the exchange algorithm. See, for example, Goos and Jones (2011, p.36) or Atkinson
et al. (2007, p.172).
In a sequential setting, extending the work of Atkinson (1999) for binary treatments, we assign treat-
ment t ∈ T to subject i by the probability given by
Ψ(ti = t | Zi, ti−1,yi−1)−1∑
t∈T Ψ(ti = t | Zi, ti−1,yi−1)−1
. (9)
This is a biased-coin type approach to treatment allocation, where the optimal decision according to
the objective function Ψ is likely to be selected, but there is random variation to avoid any suspicion
of selecting bias (Atkinson, 1982).
The evaluation of the objective function in (8) can be problematic in the context of logistic regres-
sion for two reasons. Firstly, because we have binary treatments and potentially binary covariates,
separation is more likely to occur, where a linear combination of covariates perfectly predicts the
response (Firth, 1993, Gelman et al., 2008). Separation can result in the likelihood function becoming
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monotonic and maximum likelihood estimates of the regression coefficients tending to plus or minus
infinity (Rainey, 2016). Common approaches of dealing with separation include penalizing maximum
likelihood estimates to reduce bias, and introducing a prior distribution for the regression coefficients
to shrink parameter estimates, particularly large ones, to zero. Jeffry’s prior is a common choice of
prior, and Gelman et al. (2008) recommended independent Cauchy distributions, where the probability
distribution function given the location parameter x0 and scale parameter γ is given by:
f (x | x0γ, ) = 1
piγ
(
1 +
(
x−x0
γ
)2) (10)
where the intercept has x0 = 0, γ = 10, and the slope coefficients have x0 = 0, γ = 2. We use this
recommendation by Gelman et al. (2008).
Secondly, the objective function in (8) depends on values of the model parameters. Therefore, estimates
of parameters are needed in order to design the experiment aimed to estimate these parameters in the
first place (Atkinson and Woods, 2015). We overcome this by beginning with an initial design where
we use the exchange algorithm to allocate treatments for an initial n0 units, under the assumption
that β is a vector of zeros. Responses are then obtained or generated for the first n0 subjects, and
the model is fit to obtain the first estimate of the model parameters. Algorithm 1 in the Appendix
outlines the steps in constructing a sequential optimal design.
3 Nonmyopic Approach
Having a nonmyopic approach to the treatment allocation problem means that the optimization in-
volves multiple stages. Not only is it important to consider the impact of the decision at the time of
subject i, but we consider future subjects, possibly up to subject n. The number of future subjects
considered is called the horizon, denoted N . The state at stage i comprises the information that is
known at that stage, which in our example includes the values of the covariates of subjects 1 up to i, as
well as the treatments and responses of subjects 1 up to i− 1. The decision about the treatment ti at
stage i is made based on the state Si−1 = (Zi, ti−1,yi−1). Based on that decision, there is a transition
function fi that outputs the state of the next stage, Si = fi(Si−1, ti). In our case, this transition
function is represented by a logistic model linking the responses to the treatments and covariates.
There is a need to balance two conflicting aims in the decision making:
1. The aim to exploit and to choose the treatment that most precisely estimates β in the current
state.
2. The aim to explore and to choose treatment which may not be optimal given the current state,
but may lead to gain of information which could lead to more precise estimators in later states.
Dynamic programming is an approach for solving multistage optimization problems (see, for example,
Powell, 2009). The overall problem is broken into different stages, which often correspond to points
in time, and each stage of the problem can be optimized conditionally on past states. The key idea is
that the overall sequence of decisions for treatment selection will be optimal for the entire experiment
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(Bradley et al., 1977, p. 320). The optimal design can be obtained by forward or backward induction.
We focus on backward induction since it is the approach that is usually most appropriate in problems
involving uncertainties (Bradley et al., 1977, p. 328). In backward induction, we start by finding the
optimal decision at the end of the sequence of decisions, taking into account all possible treatments
and covariates that may have been observed up until that point. Then, one can work backwards and
obtain the optimal design taking expectations of unknown quantities (Bradley et al., 1977, p.330).
See Huan and Marzouk (2016) for a recent overview of approximate dynamic programming in the
context of Bayesian experimental design. Dynamic programming has been used in some clinical trials
applications where one wishes to balance the aim of estimating the parameters (exploration) with the
aim of giving subjects the best possible treatment or obtaining maximum total revenue (exploitation).
See, for example, Cheng and Berry (2007), Ondra et al. (2019), Mueller et al. (2007) or Bartroff and
Lai (2010).
We now describe the nonmyopic approach for the binary response. To keep notation simple, we as-
sume that we have a single binary covariate and a single binary treatment, and we do not consider
interactions. We begin by constructing an initial design Xn0 with n0 subjects using the exchange al-
gorithm. We assume β = 0 as an initial guess for evaluating the objective function in the construction
of Xn0 . We then obtain responses for the first n0 subjects, yn0 , and fit the model to obtain the initial
maximum likelihood estimates of the model parameters, βˆ0.
Now, supposing that we have a design for i − 1 subjects, and we have obtained parameter estimates
βˆi−1 as a result of that design. We observe covariate value zi for the ith subject and wish to evaluate
the impact of assigning treatment ti on decisions on future possible subjects. For example, for horizon
N = 1, we consider the expected value of the objective function after i+1 subjects. Suppose treatment
ti is assigned to subject i. Since Ψ depends on yi, we need to consider the two possible responses that
yi may take, and then consider the possible values that zi+1 can take. For a given covariate value
zi+1 for subject i+ 1, we denote by t
∗
i+1(zi+1, ti, yi | zi, ti−1,yi−1) the optimal choice of treatment for
subject i+ 1 given zi+1 and ti:
t∗i+1(zi+1, ti, yi | zi, ti−1,yi−1) = arg min
ti+1
Ψ(ti+1 | zi+1, ti,yi). (11)
From here on, we suppress the conditioning and write t∗i+1(zi+1, ti, yi) for simplicity. Now, we take
the expectation of the objective function over two possible responses which may be obtained to find
an expected value of the objective function over the unknown response:
EyiΨ(ti+1 | zi+1, ti,yi) = P(yi = 0 | zi, ti,yi−1)Ψ(ti+1 | zi+1, ti,yi−1, y)
+ P(yi = 1 | zi, ti,yi−1)Ψ(ti+1 | zi+1, ti,yi−1, y),
where yi ∼ Bernoulli(pii) with pii given by:
pii =
exp
(
xiβˆi−1
)
1 + exp
(
xiβˆi−1
) , (12)
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where xi =
(
1, zi, ti
)
is the ith row of the design matrix. Now, we consider the possible covariate
values that we may observe for the next subject. We denote by P(zi = z) the probability that the ith
subject has covariate value z. In some cases, the distribution of the covariates may be known; if not,
the distribution can be estimated by the empirical distribution of the covariates of the first i subjects.
We denote by Ψ1(ti | zi, ti−1,yi−1) the expected value of the objective function when treatment ti is
assigned to subject i, taking into account the impact of the decision on one further decision in the
future. We obtain an expectation over the possible covariate combinations of the optimality criterion:
Ψ1(ti | zi, ti−1,yi−1) = Ezi+1EyiΨ(t∗i+1(zi+1, ti, yi) | zi+1, ti,yi) (13)
=
∑
z
P(zi+1 = z)EyiΨ(t
∗
i+1(zi+1, ti, yi) | zi, zi+1, ti,yi). (14)
For a horizon greater than 1, we can use the following recursive relationship to find the optimal
treatment for subject i. The expected value of the objective function after i + N subjects, when
treatment ti has been assigned, is given as follows:
For N > 0:
ΨN (ti | zi, ti−1,yi−1) = Ezi+1EyiΨN−1(t∗i+1(zi+1, ti, yi) | zi+1, ti,yi)
=
∑
z
P(zi+1 = z)EyiΨN−1(t
∗
i+1(zi+1, ti,yi) | zi, zi+1, ti,yi), (15)
and for N = 0, we have
Ψ0(ti | zi, ti−1,yi−1) = Ψ(ti | zi, ti−1,yi−1), (16)
which is simply the myopic loss after i subjects. We note that the nonmyopic approach for the logistic
model case is considerably more computationally intensive than the myopic approach.
3.1 Simulations
Our simulation compares DA-optimal designs that are constructed sequentially using myopic and non-
myopic methods. Further, we compare the nonmyopic approach where we assume the true distribution
for the covariates, and the nonmyopic approach where we use the empirical distribution of the covari-
ates obtained by finding the proportion of observed subjects with each covariate value.
Since the information matrix and the objective function depend on values of the model parameters in
the logistic model case, estimates of parameters are needed in order to design the experiment aimed
to estimate these parameters in the first place. We begin with an initial design where we use the
exchange algorithm to allocate treatments to 10 units, under the assumption that β is a vector of
zeros. In order to reduce sources of variability in our simulations, we make sure that the same initial
design is used for the myopic and non-myopic cases. Another source of variability is the generation
of the responses which are needed to obtain the estimates of the model parameters and subsequently
to evaluate the design under the objective function. When comparing the myopic and non-myopic
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designs, we generate the responses in the following way:
1. Generate a deviate ui from the Unif(0, 1) distribution.
2. Set
yi =
1 if ui ≥ pii0 if ui < pii . (17)
The deviates ui kept the same for the myopic and non-myopic approaches to try to minimize sources
of random variability in the simulation.
In our simulation, 100 units of a covariate z are generated. The covariate can take values in {−1, 1}
and is generated such that P(zi = 1) = 0.5 and P(zi = −1) = 0.5 for all i. We assume the true model
for the response is yi ∼ Bernoulli(pii) with logit(pii) = zi + ti, and generate responses according to this
model. Our simulation is constructed as follows:
I (a) 100 subjects are assumed and their covariates are generated.
(b) 100 deviates from a Unif(0, 1) distribution are generated for the response.
(c) An initial design with 10 units is constructed using an exchange algorithm withDA optimality
as the objective function.
(d) Seven sequential designs using the covariates, random deviates for the responses, and initial
design in part (a) are constructed using:
• A myopic DA-optimal design.
• A nonmyopic DA-optimal design with horizon N = 1, with the correct covariate distri-
bution assumed.
• A nonmyopic DA-optimal design with horizon N = 1, with the empirical covariate
distribution assumed.
• A nonmyopic DA-optimal design with horizon N = 2, with the correct covariate distri-
bution assumed.
• A nonmyopic DA-optimal design with horizon N = 2, with the empirical covariate
distribution assumed.
• A nonmyopic DA-optimal design with horizon N = 3, with the correct covariate distri-
bution assumed.
• A nonmyopic DA-optimal design with horizon N = 3, with the empirical covariate
distribution assumed.
(e) Designs are evaluated using the performance measure ΨDA , given by Equation (7), at each
sample size between 10 and 100, inclusive. The true values of the parameters are used to
calculate ΨDA .
II (a)-(e) above is above 20 times to obtain a distribution of the performance measure for each
sample size.
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In addition to comparing the estimates of β and the values of ΨDA for the myopic and non-myopic
designs, we also consider the efficiency of the nonmyopic design relative to the myopic design. We
define the DA-efficiencies of a design Xi relative to another design X
∗
i with parameter values β in the
logistic model case as
EffDA =
{
ΨDA (X
∗
i , β)
ΨDA (Xi,β)
}1/m
, (18)
where m is the number of non-zero rows in the matrix A.
Figure 1 displays the distributions of βˆi at each sample size between 11 and 100. The estimates appear
to be centered around their true value, β = (0, 1, 1)T , and the plots appear to be very similar across
the seven methods.
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Figure 1: Distributions of βˆi for designs for the logistic model for one covariate are plotted against
sample size. We show the myopic approach (N = 0), as well as the nonmyopic approach to constructing
DA-optimal designs with horizon N = 1 and 3. For the nonmyopic approach, we consider both the case
where the correct covariate distribution is known, and when it is unknown so the empirical covariate
distribution is used. The black line indicates the median, the dark grey indicates the 40th to 60th
percentile, and the light grey indicates the 10th to 90th percentile of the distribution.
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In Figure 2, we plot the distribution of ΨDA for each sample size between 11 and 100. We observe that
the value of this objective function decreases as sample size increases, as expected. We note that the
plots look extremely similar across the seven methods. There is is no noticeable difference between
having horizon equal to one or three. In Figure 3, we plot the relative efficiencies of the nonmyopic
designs against the myopic design, which confirms that there is no observable difference across the
methods in ΨDA ; Table 1 shows the efficiencies at the end of the experiment, and we see that the
lower bound of the 10%− 90% intervals are above 1. We observe that the myopic approach is slightly
more efficient for when sample size is below 30.
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Figure 2: Distributions of ΨDA for designs for the logistic model for one covariate are plotted against
sample size. We show the myopic approach (N = 0), as well as the nonmyopic approach to constructing
DA-optimal designs with horizon N = 1 and 3. For the nonmyopic approach, we consider both the case
where the correct covariate distribution is known, and when it is unknown so the empirical covariate
distribution is used.
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Figure 3: Distributions of the relative efficiencies of the nonmyopic DA-optimal designs against the
myopic DA-optimal designs for the logistic model for one covariate are plotted against sample size.
We consider the efficiencies of the non-myopic approach with horizons 1 and 3, with the correct and
empirical distributions, against the myopic approach as the baseline.
Table 1: Distribution of the efficiencies of the non-myopic approaches relative to the myopic approach
at the end of the experiment (n=100)
Efficiencies
when n = 100
median 40-60% interval 10-90% interval
N = 1, correct dist 1.008978 (1.005972, 1.010633) (1.000475, 1.019424)
N = 1, empirical dist 1.005368 (1.004617, 1.005720) (1.000475, 1.019424)
N = 2, correct dist 1.009279 (1.005669, 1.012720) (1.000342, 1.020574)
N = 2, empirical dist 1.012895 (1.009806, 1.013174) (1.000475, 1.035371)
N = 3, correct dist 1.005409 (1.005232, 1.007396) (1.000073, 1.016454)
N = 3, empirical dist 1.005409 (1.002690, 1.009182) (1.000477, 1.024159)
We observe in this simulation that there appears to be no benefit to the nonmyopic approach in this
setting where we have one binary treatment and one binary covariate, and the covariate is generated
such that P (zi) = 0.5 for all i. We call this a static covariate, since its distribution does not change
with i. In Section 4.1, we consider a dynamic covariate, where the distribution of the covariate changes
over time.
4 Pseudo-nonmyopic approach
One main limitation of the nonmyopic approach is that computing the nested expectations and min-
imizations over unknown quantities, such as in Equation (15), requires recursive formulae which are
computationally expensive. The number of calculations increases exponentially with each additional
future subject in the horizon and, as a result, our simulations considered examples with horizon no
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more than three. We now explore a pseudo-nonmyopic approach which involves evaluating a related
objective function with a similar aim without the use of recursion. The computational burden is re-
duced as nested expectations and minimizations are not necessary but we are still able to incorporate
information about future possible decisions. We describe this novel approach for the logistic model
case (it can easily be described for the linear model case) and provide a simulation to show how it
compares to the myopic approach.
In the pseudo-nonmyopic approach, in order to make a decision about the treatment of the ith subject,
we generate M possible trajectories of covariate values for subject i+1 until subject n. We assume, as
for the non-myopic approach, that we have a distribution fz for the covariate z. This may be the true
distribution in the population (if it is known), or an empirical approximation based on the subjects
in the trial up until the ith subject. The covariate distribution may depend on time, in which case
we refer to it as a dynamic covariate. For each of the M trajectories, we construct a pseudo-design in
which we have the i subjects and (n− i−1) subjects in the trajectory, and treatments allocated using
an approach that we describe below. We look at the average losses of the M pseudo-designs where we
assign ti = 1, and compare it to the average loss of the M pseudo-designs when ti = −1; we select ti
according to a probability that is weighted by these average losses.
This approach takes averages over simulated values of the covariates for subjects i+ 1 up to n. Opti-
mization based on Monte Carlo simulations of unknown quantities is typically conducted in a Bayesian
setting for design of experiments (Woods et al., 2017), where values of the unknown parameters may
be simulated from a prior distribution. See Gentle (2003) for an overview of Monte Carlo methods
and Ryan (2003) for an application to Bayesian design of experiments.
In order to create a design using the pseudo-nonmyopic approach for the logistic model, just like in
the sequential myopic and nonmyopic algorithms, we begin by constructing an initial design Xn0 .
This involves an exchange algorithm where we assume β = 0 as an initial guess. We then generate
responses yn0 , and fit the model to obtain the initial estimates βˆn0 .
Then, to select a treatment for subject i, for i ∈ {n0 + 1, ..., n}, we observe zi. Based on the assumed
covariate distribution fz, we generateM possible trajectories for the covariates, z
1
(i+1):n, z
2
(i+1):n, ...,z
m
(i+1):n,
where
zm(i+1):n =
(
zmi+1, z
m
i+2, ..., z
m
n
)T
, (19)
for m ∈ {1, 2, ...,M}. We then allocate treatments sequentially along each trajectory.
Given the first subject in the trajectory, zmi+1, we choose the treatment t
∗m
i+1 which minimizes the
objective function Ψ given ti, and the treatments and covariates of previous subjects and estimates
βˆi−1 based on the responses of the previous subjects, yi−1:
t∗
m
i+1
(
zmi+1, ti | zi, ti−1,yi−1
)
= arg min
ti+1
Ψ
(
ti+1 | zi, zmi+1, ti−1, ti,yi−1
)
. (20)
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To allocate a treatment for the next subject in the trajectory with covariate values zmi+2, we then
assume that t∗mi+1 has been allocated to subject z
m
i+1 and choose the treatment t
∗m
i+2 which minimizes
the objective function. We make the assumption that the future decisions are independent of the
future responses. This means that we assume the same estimate for β as in the Equation (20) and
do not update it. We continue in this way until all subjects in the trajectory have been allocated a
treatment:
For each j in {i+ 2, i+ 4, ..., n}, we define:
t∗
m
j
(
zmj , t
∗
j−1 | zi, zm(i+1):(j−1), ti−1, ti, t∗(i+1):(j−2),yi−1
)
= arg min
tj
Ψ
(
tj | zi, zm(i+1):(j), ti−1, ti, t∗(i+1):(j−1),yi−1
)
. (21)
For the mth trajectory, we obtain a pseudo-design with n subjects where the ith treatment is 1, as
well as a pseudo-design where the ith subject receives treatment −1. We denote the objective function
of the two designs as follows:
Ψ
(
tn | zi, zm(i+1):n, ti−1, ti = 1, t∗
m
(i+1):(n−1),yi−1
)
, (22)
Ψ
(
tn | zi, zm(i+1):n, ti−1, ti = −1, t∗
m
(i+1):(n−1),yi−1
)
. (23)
We define the average objective function for i = n0 + 1, ..., n − 1 across the M designs, assuming,
firstly, that ti = 1, and secondly, that ti = −1, as:
Ψ(ti = 1) =
1
M
M∑
m=1
Ψ
(
tn | zi, zm(i+1):n, ti−1, ti = 1, t∗
m
(i+1):(n−1),yi−1
)
, (24)
Ψ(ti = −1) = 1
M
M∑
m=1
Ψ
(
tn | zi, zm(i+1):n, ti−1, ti = −1, t∗
m
(i+1):(n−1),yi−1
)
. (25)
For i = n, we do not generate any future covariates so we have:
Ψ(ti = t) = Ψ (tn = t | zn, tn−1,yn−1) , (26)
for t ∈ {−1, 1}.
We sample ti from the set {−1, 1} where the probability of selecting 1 is given by
Ψ(ti = 1)
−1
Ψ(ti = 1)−1 + Ψ(ti = −1)−1
. (27)
We then observe the response yi and refit the model to obtain βˆi.
4.1 Simulations
Similarly to Section 3.1, we need to make sure that sources of variability are controlled as much as
possible so that differences between the results for the myopic and pseudo-nonmyopic approaches are
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likely to be attributable to the differences in the treatment allocation approach. We make sure that
simulations have the same initial design; the initial design is constructed with an exchange algorithm
to allocate treatments to 10 units, under the assumption that β is a vector of zeros. We fit the
models using the R function bayesglm in the arm package (Gelman and Su, 2016), with Cauchy prior
distribution with center zero and scale given by 2.5 for both the treatment and covariate parameters.
We generate deviates ui as in Equation (17) in order to generate responses yi, so that we can ensure
that the data generating mechanism is the same across simulations comparing the myopic and pseudo-
nonmyopic designs.
In this example, we have one binary covariate z. It is dynamic with a distribution given by P(zi =
1) = 0.01i. The model is given by yi ∼ Bernoulli(pii) where
logit
(
pii
1− pii
)
= zi + ti. (28)
The structure of the simulation is as follows:
I (a) 100 subjects are assumed and their covariates are generated from a specified distribution.
(b) 100 deviates from a Unif(0, 1) distribution are generated for the response.
(c) An initial design with 10 units is constructed using an exchange algorithm withDA-optimality
as the objective function.
(d) The three following sequential designs are constructed using the covariates, random deviates
for the responses, and initial design in part (a):
• A myopic DA-optimal design.
• A pseudo-nonmyopic DA-optimal design with M = 10, and the correct covariate distri-
bution assumed.
• A pseudo-nonmyopic DA-optimal design with M = 100, and the correct covariate dis-
tribution assumed.
(e) Designs are evaluated using the performance measure ΨDA at each sample size between 10
and 100, inclusive. The true values of the parameters are used to calculate ΨDA .
II (a)-(e) above is repeated 20 times to obtain a distribution of the performance measure for each
sample size.
In Figure 4, we see the estimates of β for the myopic approach, the pseudo-nonmyopic approach with
M = 10 and with M = 100. We observe that the plots looks very similar across the three methods. The
variability of the estimates reduces with sample size for the intercept and the coefficient of treatment.
The median of the distributions converge to their true value after a sample size of approximately 40.
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Figure 4: Parameter estimates given by the myopic approach, pseudo-nonmyopic approach with M =
10 and pseudo-nonmyopic approach with M = 100 for a logistic model with one dynamic covariate.
The black line indicates the median, the dark grey indicates the 40th to 60th percentile, and the light
grey indicates the 10th to 90th percentile of the distribution
In Figure 5, the top row displays the values of ΨDA evaluated at each sample size. This appears to be
similar across all methods with slightly higher variation observed for the pseudo-nonmyopic approach
with M = 10. In all three cases, the value of the objective function drops after a few initial subjects and
stabilizes after around 30 subjects. The bottom row shows the relative DA-efficiencies (see Equation
(18)) of the pseudo-nonmyopic approaches, compared to the myopic approach. We see that, initially,
they have equal efficiency, but then the myopic approach appears to be slightly more efficient. We note
that the distributions of efficiencies are skewed; there appears to be a number of extreme points where
the myopic approach is much more efficient than the pseudo-nonmyopic approach. This is partly due
to the fact that the efficiency is bounded below by zero, but unbounded above. Table 2 displays the
efficiencies at the end of the experiment; the distributions are centered around one and have greater
uncertainty than in the efficiencies of nonmyopic approach in section Table 1.
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Figure 5: Top row: D-optimality against sample size for designs for a logistic model with one dynamic
covariate. Bottom row: relative D-optimality against sample size for designs for a logistic model with
one dynamic covariate. Values below 1 indicate that the pseudononmyopic approach is more beneficial
than the myopic approach.
Table 2: Distribution of the efficiencies of the pseudo-nonmyopic approaches relative to the myopic
approach at the end of the experiment (n=100)
Efficiencies
when n = 100
median 40-60% interval 10-90% interval
M = 10 0.9690018 (0.9014291, 1.0202391) (0.6544362, 1.3059580)
M = 100 1.0157450 (0.9340631, 1.0845578) (0.6267983, 1.4871852)
We found no evidence for the benefit of the pseudo-nonmyopic approach over the nonmyopic approach
in this example. Further, we observed that the number of trajectories in the pseudo-nonmyopic
approach, M , appears to have little effect on the parameter estimates or the values of the DA-optimal
objective functions.
5 Discussion
This paper extended the sequential optimal design approach first proposed by Atkinson (1982) for the
logistic model case and for any optimality criterion. We then placed this approach in a nonmyopic
framework. In our simulations, we observed no benefit to using the nonmyopic approach over the
myopic approach. We then developed a novel methodology called the pseudo-nonmyopic approach
which is still able to take into account future possible subjects, but is less computationally expensive
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than the nonmyopic approach. Simulations showed that the pseudo-nonmyopic approach performs
similarly to the myopic approach for the logistic model case with a binary treatment.
5.1 Limitations
There are a number of limitations to our work in its ability to be directly applicable to clinical trials
and other experiments involving human subjects. Firstly, we assume responses are measured imme-
diately after treatments are given to subjects. This is not a realistic assumption so some method to
allow for a delay between treatment allocation and response could be useful. One modification would
be to allow for the method to be batch sequential; instead of allocating treatments to one subject at
a time, a group of subjects may be given optimal treatments by using the exchange algorithm. It is
also possible to incorporate delay in adaptive designs. Hardwick et al. (2006) achieve this by assuming
that subjects arrive according to a Poisson process.
Secondly, we do not consider toxicity in our work. We assume that the treatment which leads to a
better response is the more desirable treatment, but it is possible that such a treatment has unsafe
toxicity levels (Rosenberger, 1999). In our algorithms for treatment assignment, if the optimality
criterion is equal for treatment ti = 1 and ti = −1, we would assign the treatment at random. In
clinical trials, this is less likely to happen as relative efficiency of the treatments need to be considered
in conjunction with relative toxicity (Simon, 1977). In general, Rosenberger (1999) recommended
that adaptive designs should be considered after previous experiments have been able to establish low
toxicity of the treatments.
A further limitation of our work is that we arbitrarily assume in all of our simulations that we have
100 subjects in the trial. In clinical trials, there are stopping rules that determine when the trial
should terminate (Stallard et al., 2001). See Whitehead (1993) for a frequentist perspective and Berry
(1989) and Freedman and Spiegelhalter (1989) for a Bayesian perspective on stopping rules in interim
analysis. Including this element into our designs would mean that our methodology is more generally
applicable to clinical trials. Further, we may be able to make statements about relative numbers
of subjects and costs required in order to detect a significant difference in treatment effect for each
method.
5.2 Future Work
The non-myopic and pseudo-nonmyopic algorithms consider only the case where the response and
treatments are binary. Natural extensions include allowing for more complex treatment structures,
such as factorial designs, or allowing for a continuous response. Computing the expected objective
function for a continuous response would require Monte-Carlo simulations. Extending our framework
for the non-myopic approach to allow for a more general response will require greater computational
efficiency in our algorithms. This is also true of the pseudo-nonmyopic approach.
In the optimality criteria that we have considered, the response of the subjects are included in order to
update parameter estimates (optimal design methods for the logistic model case, weighted L-optimal
design). The response has not been used in order to inform treatment allocation based on the effi-
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cacy of the treatment. Covariate adjusted response-adaptive designs based on efficiency and ethics
(CARAEE) aim to optimize a utility function which takes into account the number of subjects who
receive the more effective treatment. We did some preliminary work on CARAEE designs. Here, our
optimality criterion is a function which has a component for efficiency and a component for ethics, as
well as a tuning parameter which allows the practitioner to decide which aim is more important. The
CARA (covariate adjusted response adaptive) design and RAR (response adaptive randomization)
design are special cases of the CARAEE design.
Appendix A
An R package biasedcoin is included in the Supplementary materials. The following commands im-
plement the designs for logistic regression discussed in this paper:
logit.coord: non-sequential optimal design (coordinate exchange algorithm).
logit.des: myopic sequential optimal design.
logit.nonmy: nonmyopic sequential optimal design.
simfuture.logis: pseudo-nonmyopic sequential optimal design.
The R function bayesglm in the arm package is used to fit the logistic regression model using the
Cauchy prior to avoid problems in estimation due to separation.
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Appendix B
Algorithm 1 Myopic sequential optimal design for binary response: this algorithm returns a design
matrix, constructed sequentially. The inputs are the covariate values, zn, and the number of subjects
in initial design, n0.
1: function SeqOptL(zn, n0)
2: Initialization
3: Construct initial design Xn0 using the exchange algorithm for the first n0 subjects assuming
β = 0.
4: Observe responses yn0 =
(
y1, y2, ..., yn0
)T
.
5: Fit the model assuming that the responses are distributed according to Equation (2) with
linear predictor given by Equation (4) to obtain the MLE βˆn0 .
6: for i in n0 + 1 to n do
7: Observe zi,1, ..., zi,k
8: Calculate Ψ(ti | zi, ti−1,yi−1) for each treatment.
9: Sample treatment for subject i where probability of treatment 1 is given by Equation (9).
10: Observe response yi.
11: Refit model the model with response given by yi and updated design matrix Xi and update
the parameter estimates βˆi.
12: end for
13: return X
14: end function
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